The slip
PARKINSON RECEIPTno. 16322
31 Oct 2026, 14:34 UTCdopamine neurons, braak
predictionCUL4A in dopamine neurons tracks Braak Lewy-body stage
registered8341bc157d7b5451
discovery-0.21 p=0.581 n=9
replication-0.43 p=0.244 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.21, p 0.581)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTff086882a71b1b7f243cd6d9…
follows 0da6411fa10b…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 16322: CUL4A in dopamine neurons, braak
- power
- full sample -0.30 (p 0.228, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.27 (p 0.281, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.254, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.22, sign flips 0; without severely affected donors -0.30 (p 0.228, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.64 (p 0.0039, n 18) vs -0.30 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CUL4A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CUL4A · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 1.4e-4)